Assessment of minimal residual disease in Ewing sarcoma

Lars M. Wagner, Teresa A. Smolarek, Janos Sumegi, Daniel Marmer

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Advances in molecular pathology now allow for identification of rare tumor cells in cancer patients. Identification of this minimal residual disease is particularly relevant for Ewing sarcoma, given the potential for recurrence even after complete remission is achieved. Using RT-PCR to detect specific tumor-associated fusion transcripts, otherwise occult tumor cells are found in blood or bone marrow in 20-30% of Ewing sarcoma patients, and their presence is associated with inferior outcomes. Although RT-PCR has excellent sensitivity and specificity for identifying tumor cells, technical challenges may limit its widespread applicability. The use of flow cytometry to identify tumor-specific antigens is a recently described method that may circumvent these difficulties. In this manuscript, we compare the advantages and drawbacks of these approaches, present data on a third method using fluorescent in situ hybridization, and discuss issues affecting the further development of these strategies.

Original languageEnglish (US)
Article number780129
JournalSarcoma
Volume2012
DOIs
StatePublished - Apr 18 2012

Fingerprint

Ewing's Sarcoma
Residual Neoplasm
Neoplasms
Polymerase Chain Reaction
Molecular Pathology
Neoplasm Antigens
Fluorescence In Situ Hybridization
Flow Cytometry
Bone Marrow
Recurrence
Sensitivity and Specificity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Wagner, L. M., Smolarek, T. A., Sumegi, J., & Marmer, D. (2012). Assessment of minimal residual disease in Ewing sarcoma. Sarcoma, 2012, [780129]. https://doi.org/10.1155/2012/780129

Assessment of minimal residual disease in Ewing sarcoma. / Wagner, Lars M.; Smolarek, Teresa A.; Sumegi, Janos; Marmer, Daniel.

In: Sarcoma, Vol. 2012, 780129, 18.04.2012.

Research output: Contribution to journalReview article

Wagner, LM, Smolarek, TA, Sumegi, J & Marmer, D 2012, 'Assessment of minimal residual disease in Ewing sarcoma', Sarcoma, vol. 2012, 780129. https://doi.org/10.1155/2012/780129
Wagner LM, Smolarek TA, Sumegi J, Marmer D. Assessment of minimal residual disease in Ewing sarcoma. Sarcoma. 2012 Apr 18;2012. 780129. https://doi.org/10.1155/2012/780129
Wagner, Lars M. ; Smolarek, Teresa A. ; Sumegi, Janos ; Marmer, Daniel. / Assessment of minimal residual disease in Ewing sarcoma. In: Sarcoma. 2012 ; Vol. 2012.
@article{c998a73d57c545eb86ec96acb120e77b,
title = "Assessment of minimal residual disease in Ewing sarcoma",
abstract = "Advances in molecular pathology now allow for identification of rare tumor cells in cancer patients. Identification of this minimal residual disease is particularly relevant for Ewing sarcoma, given the potential for recurrence even after complete remission is achieved. Using RT-PCR to detect specific tumor-associated fusion transcripts, otherwise occult tumor cells are found in blood or bone marrow in 20-30{\%} of Ewing sarcoma patients, and their presence is associated with inferior outcomes. Although RT-PCR has excellent sensitivity and specificity for identifying tumor cells, technical challenges may limit its widespread applicability. The use of flow cytometry to identify tumor-specific antigens is a recently described method that may circumvent these difficulties. In this manuscript, we compare the advantages and drawbacks of these approaches, present data on a third method using fluorescent in situ hybridization, and discuss issues affecting the further development of these strategies.",
author = "Wagner, {Lars M.} and Smolarek, {Teresa A.} and Janos Sumegi and Daniel Marmer",
year = "2012",
month = "4",
day = "18",
doi = "10.1155/2012/780129",
language = "English (US)",
volume = "2012",
journal = "Sarcoma",
issn = "1357-714X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Assessment of minimal residual disease in Ewing sarcoma

AU - Wagner, Lars M.

AU - Smolarek, Teresa A.

AU - Sumegi, Janos

AU - Marmer, Daniel

PY - 2012/4/18

Y1 - 2012/4/18

N2 - Advances in molecular pathology now allow for identification of rare tumor cells in cancer patients. Identification of this minimal residual disease is particularly relevant for Ewing sarcoma, given the potential for recurrence even after complete remission is achieved. Using RT-PCR to detect specific tumor-associated fusion transcripts, otherwise occult tumor cells are found in blood or bone marrow in 20-30% of Ewing sarcoma patients, and their presence is associated with inferior outcomes. Although RT-PCR has excellent sensitivity and specificity for identifying tumor cells, technical challenges may limit its widespread applicability. The use of flow cytometry to identify tumor-specific antigens is a recently described method that may circumvent these difficulties. In this manuscript, we compare the advantages and drawbacks of these approaches, present data on a third method using fluorescent in situ hybridization, and discuss issues affecting the further development of these strategies.

AB - Advances in molecular pathology now allow for identification of rare tumor cells in cancer patients. Identification of this minimal residual disease is particularly relevant for Ewing sarcoma, given the potential for recurrence even after complete remission is achieved. Using RT-PCR to detect specific tumor-associated fusion transcripts, otherwise occult tumor cells are found in blood or bone marrow in 20-30% of Ewing sarcoma patients, and their presence is associated with inferior outcomes. Although RT-PCR has excellent sensitivity and specificity for identifying tumor cells, technical challenges may limit its widespread applicability. The use of flow cytometry to identify tumor-specific antigens is a recently described method that may circumvent these difficulties. In this manuscript, we compare the advantages and drawbacks of these approaches, present data on a third method using fluorescent in situ hybridization, and discuss issues affecting the further development of these strategies.

UR - http://www.scopus.com/inward/record.url?scp=84859705583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859705583&partnerID=8YFLogxK

U2 - 10.1155/2012/780129

DO - 10.1155/2012/780129

M3 - Review article

VL - 2012

JO - Sarcoma

JF - Sarcoma

SN - 1357-714X

M1 - 780129

ER -